Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Precision Medicine in Neurodegenerative Disorders: Diagnosis, Treatment, and Management
share announcement

Precision Medicine in Neurodegenerative Disorders: Diagnosis, Treatment, and Management

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 6126

Special Issue Editor

Prof. Dr. Georgia Xiromerisiou

E-Mail Website
Guest Editor
School of Medicine, University of Thessaly, Larissa, Greece
Interests: neuodegenerative disorders; neurogenetics; movement disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Neurodegenerative disorders are characterized by progressive neuronal loss in the central nervous system, causing a decline in nervous system function.

Precision medicine (PM) is a course of treatment tailored specifically to an individual patient or subpopulation based on a particular genotype or specific biomarkers that could be indicative of the course of the disorder.

Precision medicine uses novel biomarkers, targetable disease mechanisms, pharmacogenomics, and pharmacogenetics for early diagnosis, appropriate treatment selection, tracking response to therapy, progression, and prognosis.

Its role in the diagnosis, management, monitoring, and prognosis of diseases has become more important in recent years due to the augmentation of the -omics fields, such as proteomics, metabolomics, genomics, and transcriptomics, which have allowed for PM to establish reliability as a developing domain. The use of novel biomarkers in neurodegenerative diseases has allowed for individualized therapies and prognoses to be more prevalent, increasing the accuracy of diagnoses and the efficacy of interventions based on PM.

Prof. Dr. Georgia Xiromerisiou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Precision medicine
  • Genotype
  • Proteomics, metabolomics, genomics, transcriptomics
  • Neurodegenerative disorders

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 909 KiB  
Article
Validation of Chinese Version of SKT (Syndrom Kurztest): A Short Cognitive Performance Test for the Assessment of Memory and Attention
by Yao Lu, Jingchao Hu, Mark Stemmler and Qihao Guo
Diagnostics 2021, 11(12), 2253; https://doi.org/10.3390/diagnostics11122253 - 1 Dec 2021
Cited by 3 | Viewed by 1647
Abstract
(1) Background: The SKT (Syndrom Kurztest) is a short cognitive performance test that consists of nine subtests and assesses deficits of memory and attention. This study was aimed at exploring the SKT target population in China and evaluating the reliability and validity of [...] Read more.
(1) Background: The SKT (Syndrom Kurztest) is a short cognitive performance test that consists of nine subtests and assesses deficits of memory and attention. This study was aimed at exploring the SKT target population in China and evaluating the reliability and validity of the Chinese version of the SKT; (2) Methods: A total of 1624 patients aged over 60 years old were recruited in the Sixth People’s Hospital in Shanghai. The SKT raw scores were recorded. Cronbach’s alpha coefficient was determined to assess the internal consistency reliability of the SKT. Principal factor analysis was performed to evaluate the factor structure of the SKT subtests. Correlation analyses were carried out to confirm the relationship between the modified SKT and standardized neuropsychological tests. The influence of age and educational years on SKT raw scores were detected using multiple regression analyses. Validations of the SKT subtests for detecting Mild Cognitive Impairment (MCI) from Negative Control(NC)(were determined by Receiver operating characteristic (ROC) curves; (3) Results: The internal consistency among the subtests’ scores was high: Cronbach’s α = 0.827. The SKT memory test provided a high predictive validity in detecting aMCI with a sensitivity of 90.1% and specificity of 79.3%. (4) Conclusions: Based on our experience with 1624 elderly patients in Shanghai, the Chinese version of SKT has good stability and may be a reliable and valid screening tool for detecting MCI. Full article
(This article belongs to the Special Issue Precision Medicine in Neurodegenerative Disorders: Diagnosis, Treatment, and Management)
►▼ Show Figures

Figure 1

Review

Jump to: Research

31 pages, 1112 KiB  
Review
Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments
by Linda Giampietri, Elisabetta Belli, Maria Francesca Beatino, Sara Giannoni, Giovanni Palermo, Nicole Campese, Gloria Tognoni, Gabriele Siciliano, Roberto Ceravolo, Ciro De Luca and Filippo Baldacci
Diagnostics 2022, 12(4), 796; https://doi.org/10.3390/diagnostics12040796 - 24 Mar 2022
Cited by 6 | Viewed by 3447
Abstract
The diagnosis of neurodegenerative diseases (NDDs) represents an increasing social burden, with the unsolved issue of disease-modifying therapies (DMTs). The failure of clinical trials treating Alzheimer′s Disease (AD) so far highlighted the need for a different approach in drug design and patient selection. [...] Read more.
The diagnosis of neurodegenerative diseases (NDDs) represents an increasing social burden, with the unsolved issue of disease-modifying therapies (DMTs). The failure of clinical trials treating Alzheimer′s Disease (AD) so far highlighted the need for a different approach in drug design and patient selection. Identifying subjects in the prodromal or early symptomatic phase is critical to slow down neurodegeneration, but the implementation of screening programs with this aim will have an ethical and social aftermath. Novel minimally invasive candidate biomarkers (derived from blood, saliva, olfactory brush) or classical cerebrospinal fluid (CSF) biomarkers have been developed in research settings to stratify patients with NDDs. Misfolded protein accumulation, neuroinflammation, and synaptic loss are the pathophysiological hallmarks detected by these biomarkers to refine diagnosis, prognosis, and target engagement of drugs in clinical trials. We reviewed fluid biomarkers of NDDs, considering their potential role as screening, diagnostic, or prognostic tool, and their present-day use in clinical trials (phase II and III). A special focus will be dedicated to novel techniques for the detection of misfolded proteins. Eventually, an applicative diagnostic algorithm will be proposed to translate the research data in clinical practice and select prodromal or early patients to be enrolled in the appropriate DMTs trials for NDDs. Full article
(This article belongs to the Special Issue Precision Medicine in Neurodegenerative Disorders: Diagnosis, Treatment, and Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop